MiLaboratories, renowned for its RNA immune technologies, has joined forces with Miltenyi Biotec, a trailblazer in the biotech industry, to usher in a new era of next-generation therapeutic solutions.

This strategic partnership is set to merge MiLaboratories’ state-of-the-art RNA kit technology for immune sequencing with Miltenyi Biotec’s extensive production and commercialization expertise.

Under the terms of the partnership, MiLaboratories will provide Miltenyi Biotec exclusive access to its pioneering RNA kits immune sequencing technology—a key player in propelling immunology and personalized medicine research forward. Miltenyi Biotec plans to harness its global network and biotechnological acumen to mass-produce and market these kits, thereby making them accessible to a broad spectrum of researchers and healthcare professionals globally.

A pivotal aspect of this collaboration is the incorporation of MiLaboratories’ acclaimed software solutions, MiXCR and Platforma, into Miltenyi Biotec’s product suite. These software platforms are at the forefront of next-generation sequencing (NGS) data analysis, offering robust and intuitive tools for the interpretation of genomic data. The integration ensures that customers who purchase RNA kits from Miltenyi Biotec will enjoy direct access to MiXCR and Platforma, significantly boosting their research productivity and effectiveness.

Stan Poslavsky, CEO of MiLaboratories, expressed his enthusiasm about the partnership, stating, “This alliance marks a significant chapter in our quest to expedite the creation of cutting-edge therapies. By fusing our innovative RNA technologies and software platforms with Miltenyi Biotec’s manufacturing and commercial prowess, we are set to make a meaningful impact on genomics and personalized healthcare.”

Echoing this sentiment, Jürgen Schmitz, Managing Director at Miltenyi Biotec, remarked, “We are ecstatic to collaborate with MiLaboratories, a company that echoes our dedication to enhancing human health. Their RNA kits technology for immune sequencing is a perfect fit for our molecular analysis portfolio. Additionally, their software solutions will provide our clients with unmatched support in data analysis. Together, we are laying the groundwork for the future of next-generation therapies.”

The alliance is anticipated to fast-track discoveries and advancements in genomics, equipping researchers and medical practitioners with novel tools to delve into genetic intricacies and spur the development of innovative treatment modalities.

Aptamer Group partners with biotech firm to target genetic medicines with Optimers